Literature DB >> 15085571

Study of insolubility problems of dexamethasone and digoxin: cyclodextrin complexation.

V Dilova1, V Zlatarova, N Spirova, K Filcheva, A Pavlova, P Grigorova.   

Abstract

Cyclodextrins are able to form inclusion complexes with a number of drugs if their molecular dimensions correspond to those of the cyclodextrin cavity which leads to change of physicochemical and biopharmaceutical properties of drugs. 2-Hydroxypropyl beta cyclodextrin (HP beta CD) is suitable for parenteral application because of its considerable solubility in water and low hemolytic activity. Digoxin is insoluble in water, sensitive to light and is a subject of acidic hydrolysis, it is a challenge to the technologists of parenteral dosage forms. Dexamethasone (Dex) has a very small solubility in water (0.1 mg/ml), which caused troubles by preparing liquid medicine forms. The inclusion of hydroxy acids in CD-complexes in the necessary molar proportions leads to considerable increase in the solubility of a medicine and to several times decrease of the amount of CD used. Inclusion complexation was confirmed by the results from the studies of Differential Scanning Calorimetry. The present investigation demonstrated that Digoxin/CD complex shows stability in water medium and the optimum molar ratio Digoxin/HP beta CD is 1:6. The same results can be achieved through HP beta CD, by including Dex in a multicomponent composition containing HP beta CD and citric acid in a molar ratio of 1:4:1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085571

Source DB:  PubMed          Journal:  Boll Chim Farm        ISSN: 0006-6648


  2 in total

1.  Hyaluronic acid-based hydrogels containing covalently integrated drug depots: implication for controlling inflammation in mechanically stressed tissues.

Authors:  Longxi Xiao; Zhixiang Tong; Yingchao Chen; Darrin J Pochan; Chandran R Sabanayagam; Xinqiao Jia
Journal:  Biomacromolecules       Date:  2013-10-23       Impact factor: 6.988

2.  Plasma concentration of metformin and dexamethasone after administration through Osseogate.

Authors:  Hong-Kyun Kim; Young-Seok Park
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.